Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis

Background:  The aim of the study was to assess autoimmune involvement in amyotrophic lateral sclerosis (ALS).

[1]  V. La Bella,et al.  Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis , 2009, European journal of neurology.

[2]  K. Blennow,et al.  Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype , 2007, European journal of neurology.

[3]  J. Kukal,et al.  Antibodies against light neurofilaments in multiple sclerosis patients , 2007, Acta neurologica Scandinavica.

[4]  J. Kukal,et al.  Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis , 2007, Journal of Neurology.

[5]  N. Gilhus,et al.  Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force , 2006, European journal of neurology.

[6]  A. Ludolph,et al.  Axonal damage markers in cerebrospinal fluid are increased in ALS , 2006, Neurology.

[7]  L. Siklós,et al.  Subcellular localization of IgG from the sera of ALS patients in the nervous system , 2005, Acta neurologica Scandinavica.

[8]  I. Niebroj-Dobosz,et al.  Serum IgM anti‐GM1 ganglioside antibodies in lower motor neuron syndromes , 2004, European journal of neurology.

[9]  M. Zaffaroni.  Biological indicators of the neurodegenerative phase of multiple sclerosis , 2003, Neurological Sciences.

[10]  H. Shibasaki,et al.  Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2. , 2003, Internal medicine.

[11]  E. Silber,et al.  Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit , 2002, Neurology.

[12]  S Cluskey,et al.  Mechanisms of neurodegeneration in amyotrophic lateral sclerosis , 2001, Molecular pathology : MP.

[13]  S. Nakamura,et al.  Elevation of serum soluble E‐selectin and antisulfoglucuronyl paragloboside antibodies in amyotrophic lateral sclerosis , 2000, European journal of neurology.

[14]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[15]  J. Peter,et al.  Autoantibodies in Neurodegenerative Diseases: Antigen-Specific Frequencies and Intrathecal Analysis , 1998, Neurobiology of Aging.

[16]  P. Sindou,et al.  Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis , 1998, Journal of the Neurological Sciences.

[17]  C. Wikkelsø,et al.  Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.

[18]  A. Bartoš,et al.  Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases. , 2009, Folia biologica.

[19]  G. Giovannonid,et al.  Guidelines on routine cerebrospinal fluid analysis . Report from an EFNS task force , 2006 .

[20]  R. Orrell,et al.  Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement , 2003, Acta Neuropathologica.

[21]  The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. , 1996, Archives of neurology.